Miles Capital Inc. decreased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 33.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,898 shares of the biotechnology company’s stock after selling 934 shares during the period. Miles Capital Inc.’s holdings in United Therapeutics Corporation were worth $257,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of UTHR. Ladenburg Thalmann Financial Services Inc. boosted its stake in United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock worth $104,000 after buying an additional 73 shares in the last quarter. Focused Wealth Management Inc bought a new stake in shares of United Therapeutics Corporation during the fourth quarter worth approximately $115,000. Advisory Services Network LLC bought a new stake in shares of United Therapeutics Corporation during the first quarter worth approximately $147,000. Daiwa Securities Group Inc. boosted its stake in shares of United Therapeutics Corporation by 17.4% in the first quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock worth $183,000 after buying an additional 200 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of United Therapeutics Corporation during the first quarter worth approximately $204,000.

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation (UTHR) traded down 0.21% during midday trading on Tuesday, hitting $131.15. The stock had a trading volume of 705,287 shares. The stock’s 50 day moving average price is $123.29 and its 200-day moving average price is $138.54. United Therapeutics Corporation has a 52 week low of $97.52 and a 52 week high of $169.89. The company has a market cap of $5.91 billion, a PE ratio of 9.21 and a beta of 1.56.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.12 by $0.77. The firm had revenue of $370.50 million for the quarter, compared to analysts’ expectations of $399.59 million. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The company’s quarterly revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.02 earnings per share. Equities research analysts predict that United Therapeutics Corporation will post $14.42 earnings per share for the current year.

WARNING: This article was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/miles-capital-inc-sells-934-shares-of-united-therapeutics-corporation-uthr/1359198.html.

Several research firms have recently issued reports on UTHR. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a report on Monday, April 3rd. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 2nd. Zacks Investment Research lowered United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Monday, February 27th. J P Morgan Chase & Co set a $125.00 target price on United Therapeutics Corporation and gave the stock a “hold” rating in a research report on Tuesday, April 11th. Finally, HC Wainwright reissued a “hold” rating and issued a $95.00 price objective on shares of United Therapeutics Corporation in a research report on Monday, April 17th. Four analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the stock. United Therapeutics Corporation presently has a consensus rating of “Hold” and a consensus price target of $137.09.

In other news, CEO Martine A. Rothblatt sold 1,219 shares of the stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $139.33, for a total transaction of $169,843.27. Following the sale, the chief executive officer now directly owns 1,359 shares of the company’s stock, valued at $189,349.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,218 shares of the stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $140.16, for a total transaction of $170,714.88. Following the sale, the chief executive officer now directly owns 1,358 shares in the company, valued at $190,337.28. The disclosure for this sale can be found here. Insiders have sold 18,238 shares of company stock worth $2,325,088 over the last ninety days. Insiders own 7.50% of the company’s stock.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.